Literature DB >> 19368499

Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis.

Jay R McDonald1, Angelique L Zeringue, Liron Caplan, Prabha Ranganathan, Hong Xian, Thomas E Burroughs, Victoria J Fraser, Fran Cunningham, Seth A Eisen.   

Abstract

BACKGROUND: Herpes zoster occurs more commonly in patients taking immunosuppressive medications, although the risk associated with different medications is poorly understood.
METHODS: We conducted a retrospective cohort study involving 20,357 patients who were followed in the Veterans Affairs healthcare system and treated for rheumatoid arthritis from October 1998 through June 2005. Cox proportional hazards regression was used to determine risk factors for herpes zoster and herpes zoster-free survival. Chart review was performed to validate the diagnosis of herpes zoster.
RESULTS: The incidence of herpes zoster was 9.96 episodes per 1000 patient-years. In time-to-event analysis, patients receiving medications used to treat mild rheumatoid arthritis were less likely to have an episode of herpes zoster than patients receiving medications used to treat moderate and severe rheumatoid arthritis (P < .001). Independent risk factors for herpes zoster included older age, prednisone use, medications used to treat moderate and severe rheumatoid arthritis, malignancy, chronic lung disease, renal failure, and liver disease. Among patients receiving tumor necrosis factor-alpha antagonists, etanercept (hazard ratio, 0.62) and adalimumab (hazard ratio, 0.53) were associated with a lower risk of herpes zoster. There was excellent agreement between the International Classification of Diseases, Version 9, Clinical Modification diagnosis of herpes zoster and diagnosis by chart review (kappa = 0.92).
CONCLUSIONS: Risk factors for herpes zoster included older age, prednisone use, medications used to treat moderate and severe rheumatoid arthritis, and several comorbid medical conditions. These results demonstrate that the Department of Veterans Affairs' national administrative databases can be used to study rare adverse drug events.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19368499      PMCID: PMC2743911          DOI: 10.1086/598331

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  31 in total

1.  Comorbidity measures for use with administrative data.

Authors:  A Elixhauser; C Steiner; D R Harris; R M Coffey
Journal:  Med Care       Date:  1998-01       Impact factor: 2.983

2.  Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.

Authors:  J Lazarou; B H Pomeranz; P N Corey
Journal:  JAMA       Date:  1998-04-15       Impact factor: 56.272

3.  Varicella-Zoster infection in patients with cancer.

Authors:  S Schimpff; A Serpick; B Stoler; B Rumack; H Mellin; J M Joseph; J Block
Journal:  Ann Intern Med       Date:  1972-02       Impact factor: 25.391

4.  Population-based study of herpes zoster and its sequelae.

Authors:  M W Ragozzino; L J Melton; L T Kurland; C P Chu; H O Perry
Journal:  Medicine (Baltimore)       Date:  1982-09       Impact factor: 1.889

5.  The incidence of herpes zoster.

Authors:  J G Donahue; P W Choo; J E Manson; R Platt
Journal:  Arch Intern Med       Date:  1995 Aug 7-21

Review 6.  What does epidemiology tell us about risk factors for herpes zoster?

Authors:  Sara L Thomas; Andrew J Hall
Journal:  Lancet Infect Dis       Date:  2004-01       Impact factor: 25.071

7.  Herpes zoster and human immunodeficiency virus infection.

Authors:  S P Buchbinder; M H Katz; N A Hessol; J Y Liu; P M O'Malley; R Underwood; S D Holmberg
Journal:  J Infect Dis       Date:  1992-11       Impact factor: 5.226

8.  Agreement between administrative files and written medical records: a case of the Department of Veterans Affairs.

Authors:  T M Kashner
Journal:  Med Care       Date:  1998-09       Impact factor: 2.983

9.  Granulomatous infectious diseases associated with tumor necrosis factor antagonists.

Authors:  R S Wallis; M S Broder; J Y Wong; M E Hanson; D O Beenhouwer
Journal:  Clin Infect Dis       Date:  2004-04-15       Impact factor: 9.079

10.  Herpes zoster in systemic lupus erythematosus.

Authors:  S Manzi; L H Kuller; J Kutzer; G J Pazin; J Sinacore; T A Medsger; R Ramsey-Goldman
Journal:  J Rheumatol       Date:  1995-07       Impact factor: 4.666

View more
  66 in total

1.  Sacral herpes zoster presenting as sciatica.

Authors:  Min-Hsiang Hung; Jinn-Rung Kuo; Kuo-Feng Huang; Wen-Ching Wang
Journal:  CMAJ       Date:  2010-05-25       Impact factor: 8.262

2.  Herpes zoster increased risk of neuralgic amyotrophy: a retrospective, population-based matched cohort study.

Authors:  Tsung-Yen Ho; Chi-Hsiang Chung; Yu-Ping Shen; Liang-Cheng Chen; Wu-Chien Chien; Yung-Tsan Wu
Journal:  J Neurovirol       Date:  2018-11-05       Impact factor: 2.643

3.  Therapy: The risk of herpes zoster: another cost of anti-TNF therapy?

Authors:  Tim Bongartz; Robert Orenstein
Journal:  Nat Rev Rheumatol       Date:  2009-07       Impact factor: 20.543

4.  Incidence of herpes zoster in patients with giant cell arteritis: a population-based cohort study.

Authors:  Valentin S Schäfer; Tanaz A Kermani; Cynthia S Crowson; Gene G Hunder; Sherine E Gabriel; Steven R Ytterberg; Eric L Matteson; Kenneth J Warrington
Journal:  Rheumatology (Oxford)       Date:  2010-07-13       Impact factor: 7.580

Review 5.  Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature.

Authors:  Archana Jain; Jasvinder A Singh
Journal:  Immunotherapy       Date:  2013-03       Impact factor: 4.196

6.  Chronic medical conditions as risk factors for herpes zoster.

Authors:  Riduan M Joesoef; Rafael Harpaz; Jessica Leung; Stephanie R Bialek
Journal:  Mayo Clin Proc       Date:  2012-10       Impact factor: 7.616

Review 7.  Vaccination of patients with autoimmune inflammatory rheumatic diseases.

Authors:  Johanna Westra; Christien Rondaan; Sander van Assen; Marc Bijl
Journal:  Nat Rev Rheumatol       Date:  2014-12-09       Impact factor: 20.543

8.  The risk of herpes zoster in the anti-TNF-α era: a case report and review of the literature.

Authors:  Luisa Di Costanzo; Fabio Ayala; Matteo Megna; Francesca Gaudiello; Angela Patrì; Nicola Balato
Journal:  J Dermatol Case Rep       Date:  2013-03-30

9.  Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease.

Authors:  M D Long; C Martin; R S Sandler; M D Kappelman
Journal:  Aliment Pharmacol Ther       Date:  2012-12-13       Impact factor: 8.171

10.  Herpes Zoster and Risk of Cancer in the Elderly U.S. Population.

Authors:  Parag Mahale; Elizabeth L Yanik; Eric A Engels
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-11-17       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.